{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T03:33:44Z","timestamp":1777174424931,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-68915-5","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T11:03:14Z","timestamp":1722855794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Average steps per day as marker of treatment response with anti-CGRP mAbs in adults with chronic migraine: a pilot study"],"prefix":"10.1038","volume":"14","author":[{"given":"Frederik Thal","family":"Jantzen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basit Ali","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samaira","family":"Younis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher Kjaer","family":"Cullum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thien Phu","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Beier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"68915_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina, M. et al. Migraine: Epidemiology and systems of care. Lancet 397, 1485\u20131495 (2021).","journal-title":"Lancet"},{"key":"68915_CR2","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"LJ Stovner","year":"2018","unstructured":"Stovner, L. J. et al. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 954\u2013976 (2018).","journal-title":"Lancet Neurol."},{"key":"68915_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition. Cephalalgia. 38, 1\u2013211 (2018).","journal-title":"Cephalalgia."},{"key":"68915_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1468-2982.1996.1604239.x","volume":"16","author":"MB Russell","year":"1996","unstructured":"Russell, M. B., Rasmussen, B. K., Fenger, K. & Olesen, J. Migraine without aura and migraine with aura are distinct clinical entities: A study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia. 16, 239\u2013245 (1996).","journal-title":"Cephalalgia."},{"key":"68915_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/WCO.0000000000001060","volume":"35","author":"R Messina","year":"2022","unstructured":"Messina, R., Gollion, C., Christensen, R. H. & Amin, F. A. Functional MRI in migraine. Curr. Opin. Neurol. 35, 328\u2013335 (2022).","journal-title":"Curr. Opin. Neurol."},{"key":"68915_CR6","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1111\/head.13921","volume":"60","author":"DG Rogers","year":"2020","unstructured":"Rogers, D. G., Bond, D. S., Bentley, J. P. & Smitherman, T. A. Objectively measured physical activity in migraine as a function of headache activity. Headache. 60, 1930\u20131938 (2020).","journal-title":"Headache."},{"key":"68915_CR7","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1212\/WNL.53.5.988","volume":"53","author":"WF Stewart","year":"1999","unstructured":"Stewart, W. F. et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53, 988\u2013994 (1999).","journal-title":"Neurology"},{"key":"68915_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/head.14229","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton, R. B. et al. Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The activity impairment in migraine diary. Headache 62, 89\u2013105 (2022).","journal-title":"Headache"},{"key":"68915_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-022-01433-9","volume":"23","author":"CK Cullum","year":"2022","unstructured":"Cullum, C. K. et al. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: A 52-week, single-center, prospective, observational study. J. Headache Pain 23, 61 (2022).","journal-title":"J. Headache Pain"},{"key":"68915_CR10","doi-asserted-by":"publisher","first-page":"e2124516","DOI":"10.1001\/jamanetworkopen.2021.24516","volume":"4","author":"AE Paluch","year":"2021","unstructured":"Paluch, A. E. et al. Steps per day and all-cause mortality in middle-aged adults in the coronary artery risk development in young adults study. JAMA Netw. Open 4, e2124516 (2021).","journal-title":"JAMA Netw. Open"},{"key":"68915_CR11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nature23018","volume":"547","author":"T Althoff","year":"2017","unstructured":"Althoff, T. et al. Large-scale physical activity data reveal worldwide activity inequality. Nature 547, 336\u2013339 (2017).","journal-title":"Nature"},{"key":"68915_CR12","unstructured":"Tassy, A. & Nielsen, M. B. It-anvendelse i befolkningen. Statistics Denmark. https:\/\/www.dst.dk\/Site\/Dst\/Udgivelser\/GetPubFile.aspx?id=29450&sid=itbef2020 (2020)."},{"key":"68915_CR13","unstructured":"World Health Organization. Global Recommendations on Physical Activity for Health (WHO, 2010)."},{"key":"68915_CR14","unstructured":"Santos-Longhurst, A. How many steps do people take per day on average. Healthline https:\/\/www.healthline.com\/health\/average-steps-per-day (2023)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68915-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T11:04:40Z","timestamp":1722855880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68915-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["68915"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-68915-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"5 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FTJ, SY, IN and CKC have no conflicts of interests to report. BAC reports personal fees from Pfizer, outside of the submitted work. TPD reports personal fees from Teva, outside of the submitted work. DB reports presentations (TEVA, Novartis, Pfizer), travel support (Allergan, TEVA, Pfizer, Abbvie), advisory boards (Novartis, Lilly, Teva, Lundbeck, Pfizer, Abbvie) and participations in clinical trials (TEVA, Lundbeck, Novartis, Lilly, Novo Nordic Foundation) outside the submitted work and received grants from Odense University Hospital and Rigshospitalet, University of Copenhagen and the Region of Southern Denmark not related to this work. FMA has received Honoria or personal fees from Pfizer, Teva, Novartis, Lundbeck, AbbVie and Eli Lilly for lecturing or participating in advisory boards; is principal investigator for phase IV trials sponsored by Novartis and by Teva; serves as president of Danish Headache Society and board member of the European Headache Federation; serves as associate editor for Acta Neurol Scand, Front Neurol, Front Res Pain, and Headache Medicine; serves as junior associate editor for Cephalalgia and Cephalalgia Reports; member of the editorial board of J Headache Pain.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18068"}}